Bayer of Germany has delivered figures for the first six months of 1996 in line with its expectations, and says that it is standing by its full-year targets of a 6% rise in sales and a 10% increase in pretax profits.
Pretax profits for the Bayer group in the first half of the year grew 13% to 2.7 billion Deutschemarks ($1.8 billion), mainly as a result of further productivity improvements. Another contributory factor was the income from the sale of the group's consumer care brands. Net profits were 1.5 billion marks, up 15.9%.
First-half sales were 24.8 billion marks, up 7% on the like, year-earlier period. The group said of the increase that four percentage points were attributable to the ABS plastics, printing plate and Florasynth acquisitions. Favorable exchange rate movements accounted for two percentage points, and higher selling prices one percentage point.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze